Coya Therapeutics (COYA) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan. Lucid Capital Markets is acting as sole book-running manager for the proposed public offering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support
- Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study
- Promising Outlook for COYA 302 Amidst Phase 2 Trial and Near-Term Catalysts Justifies Buy Rating
- Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302
- Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study